Growing Emphasis on Preventive Medicine Driving the Growth of the European Personalised Medicine and Pharmacogenomics Market

LONDON, July 9 /PRNewswire/ --     Given its ability to detect a disease in its very early stage,
consequently improving clinical outcomes, pharmacogenomic testing is slowly
gaining greater acceptance across Europe. Furthermore, pharmacogenomic
testing decreases the use of expensive therapies and invasive procedures, in
addition to reducing bed occupancy and burden on the healthcare system. In
Europe, age-related diseases such as cancer, Alzheimer's disease, stroke and
heart failure represent the highest cost burden to the healthcare systems.

New analysis from Frost & Sullivan (http://drugdiscovery.frost.com),
European Personalised Medicine and Pharmacogenomics Market, finds that
revenues in this market totalled US$57.1 million in 2005, and are likely 
to reach US$109.4 million in 2012.

If you are interested in a virtual brochure, which provides
manufacturers, end users and other industry participants with an overview of
the latest analysis of the European Personalised Medicine and
Pharmacogenomics Market, then send an e-mail to Radhika Menon Theodore,
Corporate Communications, at rmtheodore@frost.com with your full name,
company name, title, telephone number, fax number and e-mail address. Upon
receipt of the above information, an overview will be sent to you by e-mail.

"Considering the imminent benefits of pharmacogenomic testing,
governments across Europe have initiated campaigns to encourage the
population to be screened on certain types of diseases such as cancer, which
has significantly helped better patient management," notes Frost & Sullivan
Program Leader Dr. Fiona Rahman. "In the case of cancer, patients have more
than 90 per cent five year survival rate if their condition is detected in
the primary stages, and pharmacogenomic testing remains the foremost weapon
in the fight against cancer."

Furthermore, medical communities are increasingly stressing on preventive
medicine as the most efficacious and cost-effective approach to improving the
quality of life. In addition, researchers have realised that the most
effective way to combat diseases such as diabetes or cancer is to predict
susceptibility and begin preventive treatment before the onset of the
disease. Designing preventive screening programmes with the doctor will allow
people to be in charge of their own health. Therefore, pharmacogenomics
testing is seen to have tremendous market value.

Notwithstanding its benefits, inherent problems regarding time and cost
associated with the development of diagnostic tests remain major restraints
for market growth. Lack of education and awareness among the medical
community is an additional impediment, as physicians unfamiliar with this
novel approach are more likely to abide by traditional methods. Eventually,
patient demand could have the final say on the acceptance or rejection of
pharmacogenomics.

"With clinical applicability being the prime competitive factor in the
market, it will be crucial for pharmacogenomics developers to prove the
clinical applicability of their tests to clinicians," says Dr. Rahman.
"Clinical applicability includes the price of the test, clinical validity,
specificity, sensitivity and prevalence of adverse conditions the test is
seeking to prevent."

Going forward, companies will have to clearly demonstrate the clinical
practicality of their tests to the medical community. Apart from oncologists,
most physicians have misconceptions about the clinical practicality and do
not understand the benefits of pharmacogenomic tests. Hence, they should be
made aware of the long-term value proposition of pharmacogenomic testing in
terms of lowering the overall healthcare cost and increasing patient well
being.

European Personalised Medicine and Pharmacogenomics Market is part of the
Drug Discovery Technologies Growth Partnership Service program, which also
includes research on the following: European Molecular Diagnostics Markets,
European IVD Market and European Cancer Diagnostic Market, European Primary
Care Diagnostics. All research included in subscriptions provide detailed
market opportunities and industry trends that have been evaluated following
extensive interviews with market participants. Interviews with the press are
available.

Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more
than 40 years. The company's industry expertise integrates growth consulting,
growth partnership services, and corporate management training to identify
and develop opportunities. Frost & Sullivan serves an extensive clientele
that includes Global 1000 companies, emerging companies, and the investment
community by providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets, technologies,
econometrics, and demographics. For more information, visit
http://www.frost.com.

European Personalised Medicine and Pharmacogenomics Market H011-55

Contact:

    Radhika Menon Theodore
    Corporate Communications - Europe
    E: rmtheodore@frost.com

    Melina Trevino
    Corporate Communications - North America
    P: +1-210-247-2440
    F: +1-210-348-1003
    E: melina.trevino@frost.com

    Danielle White
    Corporate Communications - China & Latin America
    P: +1-210-247-2403
    F: +1-210-348-1003
    E: dwhite@frost.com

    Jasminder Kaur
    Corporate Communications - Asia Pacific
    P: +65-6890-0937
    F: +65-6890-0988
    E: jkaur@frost.com

    Shwetha Thomas
    Corporate Communications - South Asia & Middle East
    P: +91-22-4001-3429
    F: +91-22-2832-4713
    E: sthomas@frost.com

    Sharmin Jassal
    Corporate Communications - Australia & New Zealand
    P: +61-2-8247-8900
    F: +61-2-9252-8066
    E: sharmin.jassal@frost.com

    Patrick Cairns
    Corporate Communications - Africa
    P: +27-21-680-3274
    F: +27-21-680-3296
    E: patrick.cairns@frost.com
    http://www.frost.com